Tvardi Therapeutics, Inc. (TVRD) 10-Year Financial Performance & Capital Metrics

TVRD • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutTvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).Show more

Revenue $7M -66.0%
EBITDA -$56M +54.1%
Net Income -$71M +40.2%
EPS (Diluted) -46.59 -2418.4%
Gross Margin 88.62% +27.8%
EBITDA Margin -778.88% -34.7%
Operating Margin -781.57% -34.9%
Net Margin -992.95% -75.7%
ROE -
ROIC -2143.22%
Debt/Equity -
Interest Coverage -6.58

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 83.7% through buybacks

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 5 (bottom 5%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-32.33%

TTM-34.23%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM78.69%

EPS CAGR

10Y-

5Y-

3Y-

TTM58.47%

ROCE

10Y Avg-130.32%

5Y Avg-130.32%

3Y Avg-205.58%

Latest-175.48%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	135.08M	23.03M	41.87M	20.97M	7.14M
Revenue Growth %	-	-0.83%	0.82%	-0.5%	-0.66%
Cost of Goods Sold+	0	1.55M	7.51M	6.43M	812K
COGS % of Revenue	-	0.07%	0.18%	0.31%	0.11%
Gross Profit+	0	21.47M	34.35M	14.54M	6.33M
Gross Margin %	-	0.93%	0.82%	0.69%	0.89%
Gross Profit Growth %	-	-	0.6%	-0.58%	-0.56%
Operating Expenses+	128.68M	110.56M	121.89M	136.03M	62.11M
OpEx % of Revenue	0.95%	4.8%	2.91%	6.49%	8.7%
Selling, General & Admin	20.94M	27.98M	30.13M	27.65M	26.39M
SG&A % of Revenue	0.16%	1.21%	0.72%	1.32%	3.7%
Research & Development	107.74M	82.58M	91.76M	108.38M	32.76M
R&D % of Revenue	0.8%	3.59%	2.19%	5.17%	4.59%
Other Operating Expenses	0	0	0	0	2.96M
Operating Income+	5.38M	-89.08M	-87.53M	-121.5M	-55.78M
Operating Margin %	0.04%	-3.87%	-2.09%	-5.79%	-7.82%
Operating Income Growth %	-	-17.54%	0.02%	-0.39%	0.54%
EBITDA+	6.4M	-87.53M	-85.86M	-121.24M	-55.59M
EBITDA Margin %	0.05%	-3.8%	-2.05%	-5.78%	-7.79%
EBITDA Growth %	-	-14.68%	0.02%	-0.41%	0.54%
D&A (Non-Cash Add-back)	1.01M	1.55M	1.67M	259K	192K
EBIT	7.72M	-88.44M	-85.47M	-117.91M	-62.79M
Net Interest Income+	2.06M	603K	651K	1.32M	-5.64M
Interest Income	2.06M	603K	654K	1.32M	2.83M
Interest Expense	0	0	3K	0	8.47M
Other Income/Expense	2.33M	642K	2.06M	2.98M	-15.48M
Pretax Income+	7.72M	-88.44M	-85.47M	-118.51M	-71.27M
Pretax Margin %	0.06%	-3.84%	-2.04%	-5.65%	-9.99%
Income Tax+	-691K	0	0	0	-398K
Effective Tax Rate %	1.09%	1%	1%	1%	0.99%
Net Income+	8.41M	-88.44M	-85.47M	-118.51M	-70.87M
Net Margin %	0.06%	-3.84%	-2.04%	-5.65%	-9.93%
Net Income Growth %	-	-11.52%	0.03%	-0.39%	0.4%
Net Income (Continuing)	8.41M	-88.44M	-85.47M	-118.51M	-70.87M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	6.32	-62.77	-2.20	-1.85	-46.59
EPS Growth %	-	-10.93%	0.96%	0.16%	-24.18%
EPS (Basic)	6.39	-62.77	-2.20	-1.85	-46.59
Diluted Shares Outstanding	1.33M	1.41M	9.36M	9.36M	1.52M
Basic Shares Outstanding	1.32M	1.41M	9.36M	9.36M	1.52M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	195.06M	173.29M	44.11M	26.16M	43.83M
Cash & Short-Term Investments	180.93M	167.03M	43.74M	22.92M	37.9M
Cash Only	31.68M	13.45M	21.49M	22.92M	37.9M
Short-Term Investments	149.24M	153.58M	22.25M	0	0
Accounts Receivable	2.06M	1.15M	4.45M	4.02M	4.5M
Days Sales Outstanding	5.58	18.26	38.82	69.93	229.88
Inventory	0	2.58M	0	0	900K
Days Inventory Outstanding	-	606.92	-	-	404.56
Other Current Assets	0	0	-4.45M	-4.02M	0
Total Non-Current Assets+	76.09M	73.77M	988K	843K	0
Property, Plant & Equipment	5.12M	3.6M	460K	378K	0
Fixed Asset Turnover	26.39x	6.39x	91.02x	55.47x	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	511K	448K	0
Long-Term Investments	70.97M	70.16M	11.35M	1.5M	0
Other Non-Current Assets	0	0	-11.33M	-1.48M	0
Total Assets+	271.16M	247.06M	45.1M	27M	43.83M
Asset Turnover	0.50x	0.09x	0.93x	0.78x	0.16x
Asset Growth %	-	-0.09%	-0.82%	-0.4%	0.62%
Total Current Liabilities+	18.48M	17.62M	4.28M	3.28M	3.97M
Accounts Payable	4.89M	5.63M	2.41M	1.61M	1.43M
Days Payables Outstanding	-	1.32K	117.02	91.41	644.59
Short-Term Debt	1.6M	1.75M	1.92M	0	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	7.03M	5.28M	-1.24M	942K	1.97M
Current Ratio	10.55x	9.84x	10.31x	7.97x	11.03x
Quick Ratio	10.55x	9.69x	10.31x	7.97x	10.81x
Cash Conversion Cycle	-	-696	-	-	-10.15
Total Non-Current Liabilities+	3.67M	1.92M	85.87M	85.78M	44.45M
Long-Term Debt	0	0	0	0	44.45M
Capital Lease Obligations	3.67M	1.92M	368K	275K	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	0	85.5M	85.5M	0
Total Liabilities	22.16M	19.53M	90.15M	89.06M	48.42M
Total Debt+	5.28M	3.67M	2.37M	368K	44.45M
Net Debt	-26.41M	-9.78M	-19.12M	-22.55M	6.54M
Debt / Equity	0.02x	0.02x	-	-	-
Debt / EBITDA	0.82x	-	-	-	-
Net Debt / EBITDA	-4.13x	-	-	-	-
Interest Coverage	-	-	-29178.33x	-	-6.58x
Total Equity+	249M	227.52M	-45.05M	-62.06M	-4.59M
Equity Growth %	-	-0.09%	-1.2%	-0.38%	0.93%
Book Value per Share	187.08	161.49	-4.82	-6.63	-3.02
Total Shareholders' Equity	249M	227.52M	-45.05M	-62.06M	-4.59M
Common Stock	50K	53K	19K	19K	5K
Retained Earnings	-392.32M	-480.76M	-45.49M	-62.84M	-755.61M
Treasury Stock	0	0	0	0	0
Accumulated OCI	73K	-358K	-24K	0	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.49M	-60.09M	-17.87M	-21.04M	-60.92M
Operating CF Margin %	-0.04%	-2.61%	-0.43%	-1%	-8.54%
Operating CF Growth %	-	-9.95%	0.7%	-0.18%	-1.9%
Net Income	8.41M	-88.44M	-20.54M	-17.35M	-70.87M
Depreciation & Amortization	1.01M	1.55M	85K	95K	192K
Stock-Based Compensation	0	0	246K	314K	0
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	-7.54M	21.54M	-321K	-143K	24.86M
Working Capital Changes	-7.37M	5.26M	2.67M	-3.96M	-15.1M
Change in Receivables	-277K	912K	-3.3M	0	2.02M
Change in Inventory	0	-2.58M	0	0	-1.04M
Change in Payables	-2.78M	-1.02M	5.68M	0	-21.44M
Cash from Investing+	-20.27M	-4.75M	-22M	22.47M	48.74M
Capital Expenditures	-349K	-39K	-50K	-2.38M	-1.05M
CapEx % of Revenue	0%	0%	0%	0.11%	0.15%
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	115.98M	0
Cash from Financing+	39.14M	46.61M	4K	2K	-3.6M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	0	0	-36.47M	0
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-5.84M	-60.13M	-17.92M	-21.04M	-61.96M
FCF Margin %	-0.04%	-2.61%	-0.43%	-1%	-8.68%
FCF Growth %	-	-9.3%	0.7%	-0.17%	-1.95%
FCF per Share	-4.38	-42.68	-1.92	-2.25	-40.74
FCF Conversion (FCF/Net Income)	-0.65x	0.68x	0.21x	0.18x	0.86x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	3.38%	-37.12%	-93.69%	-	-
Return on Invested Capital (ROIC)	1.81%	-30.35%	-85.5%	-	-2143.22%
Gross Margin	-	93.25%	82.05%	69.32%	88.62%
Net Margin	6.23%	-384.06%	-204.16%	-565.21%	-992.95%
Debt / Equity	0.02x	0.02x	-	-	-
Interest Coverage	-	-	-29178.33x	-	-6.58x
FCF Conversion	-0.65x	0.68x	0.21x	0.18x	0.86x
Revenue Growth	-	-82.95%	81.81%	-49.92%	-65.96%

Frequently Asked Questions

Growth & Financials

Tvardi Therapeutics, Inc. (TVRD) reported $6.6M in revenue for fiscal year 2024. This represents a 95% decrease from $135.1M in 2020.

Tvardi Therapeutics, Inc. (TVRD) saw revenue decline by 66.0% over the past year.

Tvardi Therapeutics, Inc. (TVRD) reported a net loss of $20.9M for fiscal year 2024.

Dividend & Returns

Tvardi Therapeutics, Inc. (TVRD) had negative free cash flow of $31.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener